An interventional study of FAMES and Control in Family Members and Implementation, sponsored by Washington State University. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Washington State University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 759 studies in Psychotic Disorders with a site in United States — 97 open to participants now, 113 under way, 7 of them phase 3. Psychotic Disorders · United States.
Among the 759 studies in Psychotic Disorders with a site in United States, this one is the 26th largest by planned enrollment of the 682 interventional ones that give a count, is one of 23 that started in 2025, is one of 338 with no phase, reaches primary completion later than 96 of the 112 other live ones, and was the 716th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →97 of the 759 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18–59 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 12–30
Case Western Reserve University · Sites in United States
Ages 18–50
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
759 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 79 · Phase 2 110 · Phase 3 68 · Phase 4 121
First in 1984; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 60 across the 682 interventional studies, 123 across the 67 observational. Of the 612 that completed or were terminated, 293 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 759 have an industry lead sponsor. The 10 most frequent:
Washington State University is the lead sponsor of 83 studies on the registry; 16 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Washington State University has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
41 of the studies in Psychotic Disorders with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT05558332University of California, IrvineYouth Nominated Support Team | 2026-11 |
| NCT05457127University of California, San DiegoObstructive Sleep Apnea Treatment in Serious Mental Illness | 2026-11 |
Add all 41 to your calendar (.ics) → With an account.
Among the 759 studies in Psychotic Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Family members/support persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early stages of psychosis. The goal of FAMES is to address low family member/support person engagement in services. FAMES will also address disparities in coordinated specialty care (CSC) by using a culturally responsive family engagement strategy to be delivered by family peers.
The overall goal of this mixed-methods, clustered stepped-wedged designed study is to examine the effectiveness of a family peer implemented in coordinated specialty care programs at engaging family members in services. The use of a family peer is anticipated to increase family member participant's feelings of connectedness, self-efficacy, and motivation which will in turn improve family member participants engagement in scheduled coordinated specialty care services such as family psychoeducation.
Recruitment will consist of dyads compromised of a family member support person and a corresponding individual receiving coordinated specialty care services. Recruitment will occur over two waves, the attention control condition (ACC) and the FAMES condition. The ACC will last for 18 months and will recruit 225 participant dyads during which time family member participants will be contacted weekly for 12 weeks where they will be provided with positively framed messaging, educational materials around psychosis, tips for addressing relevant concerns in areas such as communication and de-escalation, and a list of community-based and online resources and events. The FAMES condition will last for 30 months and will recruit 225 participant dyads during which time family member participants will receive a modified cultural formulation interview, brief check-ins, psychoeducation, and will have access to an online community.
Recruitment will take place at nine coordinated specialty care programs across four states (Washington, Oregon, Tennessee, and New Mexico) which have been randomized to a clustered stepped wedge program design.
Family Member / Support Person Inclusion Criteria:
Exclusion Criteria:
Primary Service User Inclusion Criteria
Exclusion Criteria
225 dyads (family members/support persons and individuals receiving services for psychosis) will be recruited over a period of 18 months to receive 12 weeks of weekly communication via text, email or phone call, which includes positive messaging, community resources, appointment reminders, and psychoeducation.
Behavioral: Control
This arm lasts for 30 months during each wave of the clustered randomized stepped wedge design. 225 participants will receive the FAMES intervention.
Behavioral: FAMES
225 dyads (family member/support persons and individuals receiving services for psychosis) will be recruited over a period of 30 months. Family member/support persons will be connected to a family peer for a period of 12 weeks who will use the cultural formulated interview to develop rapport and identify unique cultural needs which can inform treatment and resource identification. Participants will receive brief contact, family psychoeducation, and be connected to an online family resource group where they can receive additional support from certified peers and other family member/support persons.
participants will receive 12 weeks of automated communication which contain positive messaging, appointment reminders, links to community resources, and coping skills.
Engagement in coordinated specialty care psychoeducation
Will be measured as first session attendance rate and total attendance rate per family provided by administrative data from the coordinated specialty care site partners.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 3 months
Engagement in Family Engagement Strategy
Total number of Family Engagement Strategy session attended and the total number of contact minutes to measure engagement.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 3 months
Perceived Stress Scale
A self-report measure which includes 10 Likert-style items to assess the degree to which an individual appraises life as stressful. Scores range from 0-40 where scores greater that 13 indicate moderate to high perceived stress.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
General Anxiety Disorder - 7
Self-report measure to assess symptoms of anxiety. Scores range from 0-21 where scores greater than 10 are indicative of clinically significant anxiety.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
Client Engagement
Provider reported service utilization. Total number of appointments attended.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
Client - Patient Health Questionnaire - 9
A self-report from the individual receiving coordinated specialty care services on their symptoms of depression. Scores range from 0-27 where any score 10 or greater is indicative of clinically significant symptoms of depression.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
Family - Patient Health Questionnaire - 9
A self-report from the family member participant on their symptoms of depression. Scores range from 0-27 where any score 10 or greater is indicative of clinically significant symptoms of depression.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
Community Assessment of Psychic Experiences - Positive Scale 15-items Scale
A self-report measure from the individual receiving the coordinated specialty care services. Scores range from 0-3 where scores greater than 1.46 indicate clinically significant symptoms of psychosis.
Time frame: Baseline through study completion; repeated measure to assess change through study completion, average of 6 months
General Self-Efficacy Scale
A self-report 10-item measure completed by the family member participant. Scores range from 10-40 with higher scores indicating greater self-efficacy.
Time frame: Baseline and Month 3 of treatment period; repeated measure to assess change through study completion, an average of 3 months
Social Connectedness subscale of the Youth Services Survey - Families
Social connectedness will be measured using four questions (e.g., "I know people who will listen and understand me when I need to talk") from the YSS-F. Scores range from 4 to 20, higher scores indicating greater social connectedness.
Time frame: Baseline and Month 3 of treatment period; repeated measure to assess change through study completion, an average of 3 months
Treatment Motivation Questionnaire
A self-report measure completed by the family member/support person participant. Includes 26 Likert-scale questions to assess motivation about services. Scores range from 27 to 182 where greater scores indicated greater motivation.
Time frame: Baseline and Month 3 of treatment period; repeated measure to assess change through study completion, an average of 3 months
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Dec 2029, 57 months after the start.
Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 57 months is above that.
Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington State University